Erasca Appoints Former Genentech/Roche Oncology Head as President of R&D, Grants 1.3M Options
ERAS has more than doubled off its 52-week low of $1.33.
Summary
Erasca appointed Dr. Charles S. Fuchs, former Genentech/Roche oncology head, as President of R&D, granting 1.3 million stock options and adopting a new 6.2-million-share inducement plan.
Key Events · Executive and Board Changes · ERAS
-
High-Profile R&D Leadership Hire
Dr. Charles S. Fuchs, former SVP and Global Head of Oncology at Genentech/Roche, appointed President of R&D effective August 10, 2026. He previously led Yale Cancer Center and Dana-Farber's GI oncology division.
-
Inducement Plan Adopted
Board adopted the 2026 Employment Inducement Incentive Award Plan, reserving 6.2 million shares for equity awards to new hires, without stockholder approval under Nasdaq rules.
-
Equity Grant to New President
Dr. Fuchs received 1.3 million stock options (1,278,520 under the Inducement Plan), vesting over four years with 25% after year one, at an exercise price equal to the grant-date closing price.
-
Compensation Package
Annual base salary of $570,000 with a target bonus of 45% of base salary, plus eligibility for severance and change-in-control benefits under the company's Severance Plan.
Analysis · ERAS · Life Sciences
Erasca named Dr. Charles S. Fuchs, former global head of oncology at Genentech/Roche, as President of R&D. The hire brings deep oncology drug development expertise at a critical time — the company recently faced a major stock drop and legal challenges after disclosing a patent dispute and a patient death in a clinical trial. The board also adopted an inducement plan reserving 6.2 million shares, with 1.3 million options granted to Dr. Fuchs. This signals a strategic push to strengthen leadership and reassure investors about the pipeline's future.
At the time of this filing, ERAS was trading at $18.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.3B. The 52-week trading range was $1.33 to $24.28. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.